CompletedNot Applicable

Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer

United States175 participantsStarted 2023-04-01

Plain-language summary

This study aims to establish an exosome-based liquid biopsy signature to detect molecular residual disease (MRD) in stage II-III colorectal cancer (CRC) patients. Identifying patients with MRD after surgery is crucial for selecting appropriate candidates for adjuvant chemotherapy (ACT), allowing for more personalized treatment approaches and potentially improving patient outcomes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with pathologically confirmed stage II or III colorectal cancer.
✓. Patients who have undergone curative-intent surgery.
✓. Patients with no evidence of distant metastasis (stage IV).
✓. Patients aged 18 years or older.
✓. Patients who provided written informed consent.

Exclusion criteria

✕. Patients with stage IV cancer or those receiving neoadjuvant therapy.
✕. Patients with non-curative resection or requiring urgent surgery.
✕. Patients with a follow-up period of fewer than 3 years.
✕. Patients with severe comorbidities or who are unable to participate in follow-up assessments.

What they're measuring

Tumor Evaluation (Recurrence)

Timeframe: Follow-up at regular intervals during the first 3 years post-surgery.

Trial details

NCT IDNCT06654622

SponsorCity of Hope Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-01-18

View on ClinicalTrials.gov More Colo-rectal Cancer trials